Answers are grounded in this paper and cite their sources.
Post-transplant skin and soft tissue cancer (SSTC) risk in non-White solid organ transplant recipients remains poorly characterized. In this single-center, matched cohort study of 69 non-White and 133 White heart transplant recipients at Tufts Medical Center from February 2013 through April 2023, SSTCs were observed less frequently in non-White recipients (4.3% vs. 18.8%). While Non-White patients exclusively developed squamous cell carcinomas (3/3), a predominance of basal cell carcinomas was observed in White recipients (30/50). Non-White recipients also had lower rates of dermatologic follow-up (39% vs. 59%). Though limited by small sample size and short follow-up duration, among others, these data highlight the need for larger multicenter studies to optimize counseling and surveillance for SSTCs in diverse post-transplant populations.
No takes yet. Share an insight, caveat, or question.
Mologousis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: